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Objective. Multiple mechanisms are involved in pain associated with osteoarthritis (OA). The painDETECT and Self-
Report Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaires screen for neuropathic pain and
may also identify individuals with musculoskeletal pain who exhibit abnormal central pain processing. The aim of this
cross-sectional study was to evaluate painDETECT and S-LANSS for classification agreement and fit to the Rasch model,
and to explore their relationship to pain severity and pain mechanisms in OA.
Methods. A total of 192 patients with knee OA completed questionnaires covering different aspects of pain. Another
group of 77 patients with knee OA completed questionnaires and underwent quantitative sensory testing for pressure–
pain thresholds (PPTs). Agreement between painDETECT and S-LANSS was evaluated using kappa coefficients and
receiver operator characteristic (ROC) curves. Rasch analysis of both questionnaires was conducted. Relationships
between screening questionnaires and measures of pain severity or PPTs were calculated using correlations.
Results. PainDETECT and S-LANSS shared a stronger correlation with each other than with measures of pain severity.
ROC curves identified optimal cutoff scores for painDETECT and S-LANSS to maximize agreement, but the kappa
coefficient was low (  0.33–0.46). Rasch analysis supported the measurement properties of painDETECT but not those
of S-LANSS. Higher painDETECT scores were associated with widespread reductions in PPTs.
Conclusion. The data suggest that painDETECT assesses pain quality associated with augmented central pain processing
in patients with OA. Although developed as a screening questionnaire, painDETECT may also function as a measure of
characteristics that indicate augmented central pain processing. Agreement between painDETECT and S-LANSS for pain
classification was low, and it is currently unknown which tool may best predict treatment outcome.
INTRODUCTION
Pain is a major symptom of patients with osteoarthritis
(OA) and has a variety of characteristics suggesting differ-
ing underlying mechanisms (1). A range of approaches to
pain management using analgesics, both those used in
clinical practice and those in development, target discrete
pain mechanisms. Heterogeneity between patients in the
predominant mechanisms of OA pain may contribute to
poor responses to treatment with specific agents. Valid
tools are required to identify patients with OA who may
respond to treatments targeting specific pain mechanisms.
Although OA is traditionally considered to be noci-
ceptive, some patients describe aspects of their pain
as burning or shooting. Such characteristics suggest
mechanisms that are shared with neuropathic pain (2).
The painDETECT questionnaire (3) and the Self-Report
Leeds Assessment of Neuropathic Symptoms and Signs
(S-LANSS) scale (4) were developed to help with the
diagnosis of neuropathic pain. PainDETECT classifies
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subjects into groups based on a summative score for 9
items: neuropathic pain component is unlikely (score
12), result is ambiguous (score 13–18), and neuropathic
pain component is likely (score 19). Most items use a
6-point scale in which higher scores are suggestive of
greater intensity. PainDETECT was originally developed
for individuals with low back pain and showed good sen-
sitivity (85%) and specificity (80%) when compared with
a clinical diagnosis of pain of a predominantly nociceptive
origin (e.g., visceral pain) or neuropathic origin (e.g., post-
herpetic neuralgia) (3).
S-LANSS uses a binary response system requiring sub-
jects to confirm whether or not they have experienced a
symptom. It uses a summative score for 7 items to classify
subjects into 2 groups: pain is not of a predominantly
neuropathic origin (score 12) and pain is of a predomi-
nantly neuropathic origin (score 12). S-LANSS exhibited
good sensitivity (74%) and specificity (76%) when com-
pared with clinical assessment of pain type across groups
of individuals with primarily nociceptive conditions
(e.g., headaches) or neuropathic conditions (e.g., nerve
entrapment) (4). Hochman et al (5) compared a modified
painDETECT questionnaire with the S-LANSS scale in
patients with knee OA and observed a strong positive
correlation (  0.73, P  0.0001). However, those inves-
tigators did not control for pain intensity and did not
examine agreement between classifications.
Although painDETECT and S-LANSS were developed to
classify neuropathic pain, these instruments have also
been used to measure neuropathic pain–like symptoms
(6,7). Associations of high painDETECT scores with a low
(more sensitive) pressure–pain threshold (PPT) (8) suggest
that these pain qualities are associated with augmented
pain processing, even in persons without clinical evi-
dence of neuropathy (9). PPTs are also reduced in patients
with OA, both remote and distal from the affected joint,
suggestive of augmented central pain processing, which is
also known as central sensitization (10). Hochman et al
(11) observed that patients with knee OA and modified
painDETECT scores of 12 had an increased chance of
displaying signs of central sensitization relative to patients
with scores of 12. Central sensitization in knee OA may
be attributable to chronically painful stimulation from the
affected joint (5) and neuroimmune interactions in the
central nervous system.
It is important to examine the measurement properties
of the questionnaires, because both have been used as
measurement scales. This can be achieved with Rasch
analysis, which has several statistical advantages, includ-
ing (given fit to the model) transformation of raw scores
into interval-level data, thereby facilitating, for example,
valid analysis of changes in data following an intervention
(12). An earlier version of LANSS was not shown to fit the
Rasch model in patients with OA (13), but Rasch analyses
of S-LANSS and painDETECT have not been reported.
The aim of this study was to optimize and compare
properties of painDETECT and S-LANSS as classification
and measurement questionnaires in patients with knee
OA. Relationships between these questionnaires and mea-
sures of pain intensity were investigated to explore possi-
ble confounding by pain severity and their potential for
use in phenotyping. Associations between painDETECT
scores and PPTs were assessed to examine the extent to
which this questionnaire measures augmented central
pain processing.
PATIENTS AND METHODS
Patients with radiographic evidence of knee OA and ac-
companying pain on most days for the past month were
recruited to participate in a cross-sectional questionnaire
study between December 2010 and July 2011 (for review,
see ref. 14). Radiographs obtained from the patients were
scored using the Kellgren/Lawrence system, and scores of
2 were used to define radiographic OA. Approximately
half of the patients were identified from a previous study
(15), and the remaining patients were recruited from clin-
ics in Nottingham University Hospitals NHS Trust and
Sherwood Forest Hospitals NHS Foundation Trust. Exclu-
sion criteria were another inflammatory rheumatic condi-
tion (e.g., rheumatoid arthritis, psoriatic arthritis, gout, or
fibromyalgia), knee joint surgery within the last 3 months,
and an inability to understand English or otherwise com-
plete the questionnaires.
Potential participants were sent an invitation to com-
plete a questionnaire set covering different aspects of pain.
Questionnaires were completed at home and returned by
prepaid envelope. Data are reported from the McGill Pain
Questionnaire (MPQ) pain rating index and present pain
intensity scale (16), Intermittent and Constant Osteoarthri-
tis Pain scale (ICOAP) (17), RAND 36-Item Short Form
Health Survey pain subscale (18), painDETECT, and S-
LANSS (including a 0–10 numerical rating scale for pain
intensity). At the start of the study, the patients were
informed that questions about their pain pertained to OA-
related knee pain (5). Patients with bilateral OA knee
pain were permitted to choose which joint(s) to rate, to
permit an evaluation of their overall pain experience. The
Significance & Innovations
● Although painDETECT and the Self-Report Leeds
Assessment of Neuropathic Symptoms and Sign
may classify people with knee osteoarthritis (OA)
according to a pain phenotype, potentially repre-
senting augmented central pain processing, the
level of agreement between the classifications
made by these questionnaires is low. Further work
is required to establish the accuracy of these ques-
tionnaires as stratification tools in this condition.
● Rasch-converted painDETECT scores may func-
tion as a measurement scale for the extent of aug-
mented pain processing in people with knee OA.
● Questionnaires that classify pain mechanisms in
people with OA could help target treatments to
those who are most likely to benefit, and identify
subgroups of patients suitable for recruitment to
clinical trials.
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patients were permitted to continue their usual medica-
tion regimen during the study. Approval was granted by
Nottingham Research Ethics Committee One, and all par-
ticipants provided informed consent.
Pressure–pain thresholds. A separate sample of pa-
tients with clinically diagnosed OA and accompanying
knee pain was recruited from primary and secondary care
services through another questionnaire study, in order to
measure PPTs; radiographs were not scored for these pa-
tients. As part of the questionnaire study, these patients
were provided an information sheet that included a sec-
tion on PPT testing and were invited to indicate on their
consent form if they were interested in participating.
Those interested were telephoned to confirm eligibility
and to arrange a time for the test. The same exclusion
criteria applied, but patients were also required to be able
and willing to travel and undergo PPT testing. In addition
to the larger questionnaire, the patients also completed
painDETECT, a pain body map, and the ICOAP scale; all of
these questionnaires were completed at home. On the day
of testing (an average of 34 days after the questionnaires
were administered), the patients rated their worst knee
pain over the last week on a scale from 0 (no pain) to 10
(pain as severe as it could be) (4). Testing was performed
between March 2012 and July 2013 at Nottingham City
Hospital or Queen’s Medical Centre.
PPTs were measured by 1 of 2 female researchers, using
an electronic pressure algometer (SENSEBox; Somedic).
The algometer had a 1-cm–diameter probe, which was
applied with increasing pressure at a rate of 50 kPa/
second. When patients pressed a switch to indicate that
the application was experienced as pain, the probe was
immediately retracted, and stimulation ceased. Patients
were familiarized with the testing procedure by applica-
tion of the stimulus to their fingernail. PPTs were recorded
at 3 sites in reference to their more painful knee (10):
sternum, ipsilateral medial tibiofemoral joint line, and
anterior tibia. The probe was placed on each site 3 times.
To avoid temporal summation effects, there were 2-minute
rest intervals between testing at the 3 sites.
Statistical analysis. Kappa coefficients (19) were
used to examine agreement between painDETECT and
S-LANSS classifications (20). Receiver operating charac-
teristic (ROC) curves were plotted to maximize agree-
ment between questionnaires (21,22). Kappa coefficients
and ROC curves were calculated using SPSS version 21.0.
In lieu of a gold standard for neuropathic pain (5),
painDETECT and S-LANSS were used as screening mea-
sures and as the standard for comparisons. The area under
the curve was reported for each ROC curve, and the
Youden Index and the point on the ROC curve closest to
(0, 1) (21) were used to identify optimal cutoffs. To explore
relationships between painDETECT, S-LANSS, and mea-
sures of pain severity, Spearman’s correlation coefficients
were calculated in SAS, version 9.1. Rasch-converted
scores were used in correlation analyses for both the ques-
tionnaire study and the PPT substudy, when available (for
review, see ref. 14). Use of ICOAP subscale scores was
supported by previous analyses (14). When appropriate,
95% confidence intervals (95% CIs) were calculated.
Rasch analysis (23) concerns assessment of fit between
questionnaire data and predictions of the Rasch model.
Several reviews (12,24,25) of Rasch analysis have detailed
the process and defined terminology; therefore, only a
brief overview is provided here. Analysis was conducted
in RUMM2020 (26) using the dichotomous and partial
credit models (27). Summary fit residuals (mean  SD) for
items and persons and chi-square testing for item–trait
interactions were used to evaluate overall fit. Individual
items and persons were also assessed for fit using standard
criteria (i.e., 2.5 fit residuals 2.5; chi-square and ana-
lysis of variance [ANOVA] tests for items, with Bonferroni
correction). Questionnaires were checked for disordered
response thresholds, differential item functioning (DIF) for
sex and age (age 64 years, age 64–71 years, and age 71
years), response dependency, and unidimensionality (for
review, see ref. 14). The person separation index (PSI) was
reported for each scale.
An arithmetic average was calculated for PPTs at each
site and compared using Friedman’s ANOVA by ranks,
with pairwise comparisons. Associations between PPTs
and Rasch-transformed painDETECT scores used Spear-
man’s correlation coefficients and partial correlations,
controlling for constant and intermittent ICOAP scores.
Demographics and pain scores were compared between
the questionnaire study and the PPT substudy using
Mann-Whitney U and chi-square tests. These tests were
also conducted to compare patients included in the
ROC curve analysis and those who were not, and to com-
pare patients for whom there was agreement between
painDETECT and S-LANSS pain classifications and pa-
tients for whom there was no agreement. Patients with
missing questionnaire data were included in the Rasch
analyses of painDETECT and S-LANSS and therefore
Rasch-based correlations with these questionnaires, be-
cause the Rasch model can handle missing data (28) (see
Supplementary Table 1 and Table 2, available in the on-
line version of this article at http://onlinelibrary.wiley.
com/doi/10.1002/acr22431/abstract). These patients were
not, however, included in the other analyses (e.g., ROC
curves and correlations in the PPT substudy) or used with
the other questionnaire scores.
Sample size calculations for the questionnaire study
were based on Rasch analysis. Approximately 150 patients
were required in order to have at least 95% confidence
that item calibrations were within 0.5 logits (29). A cor-
relation of approximately 0.3 was expected between
painDETECT and PPT sites, based on pilot study work.
Eighty-three patients would be needed to have 80% power
for this effect size. Although fewer patients were entered
into the substudy, the effect size was larger than antici-
pated.
RESULTS
Of the 474 patients invited to take part in the questionnaire
study, 192 were eligible and agreed to participate. Of the
171 patients who responded, 83 (49%) self-reported pain
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localized to their knee(s) on the MPQ body map (27%
unilateral and 21% bilateral), and 88 (51%) also reported
pain in other areas. Additional characteristics of the pa-
tients are shown in Table 1. The painDETECT question-
naire was completed by 179 patients, but 29 had missing
data. Twenty-seven percent of the patients had a score of
19. S-LANSS was completed by 180 participants, but 18
had missing data. A score of 12 was obtained by 30%
of the patients. Complete data on both questionnaires
were available for 135 patients (ROC subsample; see
Table 1). There were no significant differences between
demographic characteristics and the majority of pain
scores for patients with and those without complete data
on both screening questionnaires. However, available
painDETECT scores were significantly higher for patients
without complete data on S-LANSS (P  0.05).
Comparing classifications. Fair agreement (20) was ob-
served for classification as probable neuropathic pain ( 
0.35 [95% CI 0.16, 0.51], P  0.001) using painDETECT
and S-LANSS cutoffs of 19 and 12, respectively. Al-
though the questionnaires showed agreement for pain
classifications in 100 patients (74%), they showed dis-
agreement in 35 patients (26%). In 21 of these 35 patients,
pain was classified by S-LANSS as primarily neuropathic
and by painDETECT as unlikely neuropathic or as an
ambiguous result; for the remaining 14 participants, the
opposite was observed. No significant differences were
observed for demographic characteristics and the majority
of pain scores between patients whose classifications were
agreed upon and those whose classifications were not
agreed upon. However, summary median painDETECT
and S-LANSS scores were significantly higher (both P 
0.001) in the group in which classifications were dis-
agreed upon than in the group in which classifications
were agreed upon, despite producing different pain clas-
sifications on an individual patient level in the former
group.
ROC curves were constructed (Figure 1) to deter-
mine whether the published cutoffs could be altered to
maximize classification agreement. Optimal cutoffs for
painDETECT were 12 (90% sensitivity and 62% speci-
ficity) or 14 (78% sensitivity and 74% specificity), and
those for S-LANSS were 5 (91% sensitivity and 56%
specificity) or 9 (73% sensitivity and 71% specificity),
each using the Youden Index or the point on the ROC
curve closest to (0, 1), respectively. These new cutoffs for
painDETECT moderately improved classification agree-
ment ( 0.42 [95% CI 0.29, 0.56], P 0.001 and  0.46
[95% CI 0.31, 0.61], P  0.001, respectively) but the new
cutoffs for S-LANSS resulted in negligible change ( 
0.33 [95% CI 0.21, 0.45], P  0.001 and   0.36 [95% CI
0.20, 0.52], P  0.001, respectively).
Rasch analysis of painDETECT. The item about the
“course” of the patient’s pain uses a negative scoring
weight that cannot be entered into RUMM2020. Therefore,
1 was added to each of the scoring weights for this item.
However, because this approach resulted in misfit (Table
2) and a high positive fit residual of 6.25, further analyses
were conducted without this item.
Table 1. Demographic characteristics of the patients and descriptive statistics for the questionnaire study,
the ROC subsample, and the PPT substudy*
Questionnaire study
(n  192)
ROC subsample
(n  135)
PPT substudy
(n  77)
Patient characteristics
Age, mean  SD years 67  10 67  10 68  9
Duration of pain, mean  SD years 9  9 10  10 5  5
Sex, % female 53 51 56
Questionnaire scores
painDETECT (possible range 1–38) 13 (8–19) 13 (7–18) 13 (8–18)
S-LANSS (possible range 0–24) 8 (2–13) 7 (2–13) N/A
NRS (possible range 0–10) 7 (5–8) 7 (6–8) 7 (5–8)
MPQ PRI (possible range 0–78) 16 (11–24) 17 (11–25) N/A
MPQ PPI (possible range 0–5) 2 (2–2) 2 (2–2) N/A
ICOAP, constant (possible range 0–100) 45 (30–65) 45 (30–60) 53 (36–65)
ICOAP, intermittent (possible range 0–100) 50 (38–67) 50 (38–67) 54 (43–70)
RAND SF-36 pain subscale (possible range 0–100) 45 (23–58) 45 (25–58) N/A
PPT, kPa (possible range 0–1,600)
Sternum N/A N/A 197 (118–300)
Medial tibiofemoral joint line† N/A N/A 235 (150–372)
Anterior tibia N/A N/A 159 (106–250)
* Except where indicated otherwise, values are the median (interquartile range). Because of missing data, sample sizes used for
calculating the descriptive statistics varied from 150 to 178 for the questionnaire study, from 115 to 135 for the receiver operating
curve (ROC) subsample, and from 71 to 77 for the pressure–pain threshold (PPT) substudy. Missing data or unclear responses
were recorded for 11–67 patients across the 3 samples. The duration of pain was based on patient self-reports. The numerical
rating scale (NRS) portion of the Self-Report Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaire
was completed on the day of test in the PPT substudy. MPQMcGill Pain Questionnaire; PRI pain rating index; PPI present
pain intensity; ICOAP  Intermittent and Constant Osteoarthritis Pain; RAND SF-36  RAND 36-Item Short Form Health
Survey.
† Values could not be obtained in 4 patients.
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Two items exhibited marginally disordered thresholds
(item 1, “burning sensation” in the painful areas; item 5,
“cold or heat” is “occasionally painful”); however, be-
cause rescoring did not substantially affect fit, these items
were left unaltered. Summary fit statistics indicated ade-
quate fit and a unidimensional scale (Table 2). None of
the remaining items misfit the model, but 5 patients had
high negative fit residuals. Removal of these items did not
particularly improve fit, and they were retained. For item
3 (“light touching” is painful), the expected values for
women were higher than those for men, and for item 6
(“numbness” in the painful areas), the expected values for
men were higher than those for women. Combining these
items into a subtest resolved the DIF, indicating that the
effects cancelled each other out; therefore, no remedial
action was necessary. Items 1 and 2, which refer to similar
sensations (“burning sensation” [e.g., stinging nettles] and
“tingling or prickling”) exhibited response dependency.
Grouping these items into a subtest improved fit (Table 3).
Figure 2 shows that painDETECT was reasonably targeted.
However,20% of the patients had low trait levels, which
were not measured.
Figure 1. Self-Report Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) (A) and painDETECT (B) receiver operating
characteristic (ROC) curves for classification of neuropathic pain, as determined by the respective questionnaires. Each ROC curve
indicates above-chance performance (for S-LANSS, area under the curve [AUC] 0.79, 95% confidence interval [95% CI] 0.71, 0.88; for
painDETECT, AUC 0.82, 95% CI 0.74, 0.89), but no clear cutoff point.
Table 2. Fit statistics in the Rasch analyses of painDETECT and S-LANSS*
Analysis
Item fit
residual,
mean  SD
Person fit
residual,
mean  SD 2(df) [P]
Person
separation
index
Percent of
significant t-tests
(95% CI)
painDETECT
All items 0.52  2.33 0.10  0.99 102.67 (18) [0.05] 0.78 3.98 (0.80–7.20)
Minus item about course of pain 0.59  1.10 0.19  1.05 19.82 (16) [0.23] 0.83 5.81 (2.60–9.10)
Subtest items referring to “burning”
and “tingling”
0.71  0.92 0.16  0.97 12.51 (14) [0.57] 0.82 4.68 (1.40–7.90)
S-LANSS
All items 0.19  1.37 0.03  0.72 29.03 (14) [0.01] 0.68 0
Minus item 4 0.26  0.86 0.02  0.73 22.45 (12) [0.03] 0.68 0
Minus item 6 0.35  0.65 0.02  0.73 27.18 (10) [0.05] 0.59 *
Ideal values 0  1 0  1 [0.05] 0.7 5
* It was not possible to run the t-test procedure in RUMM2020 for the last step of the Self-Report Leeds Assessment of Neuropathic Symptoms and
Signs (S-LANSS) analysis due to the small set of items. Determination of the percent of significant t-tests is used to examine unidimensionality of the
scale. A principal components analysis of the residuals is conducted to identify the 2 most divergent subsets of items. These subsets are then used to
generate separate person estimates that are compared using a series of t-tests. In a unidimensional scale, no more than 5% of these tests should show
significance at a level of 0.05. A binomial confidence interval (CI) is used for these analyses.
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Rasch analysis of S-LANSS. The summary fit residual
for the items was high, and the chi-square test value was
significant (Table 2). The PSI was low and met only the
minimum required value for group use when rounded to 1
decimal place (12). Item 4 (pain comes on “suddenly and
in bursts”) had a high positive fit residual of 3.00. Removal
of this item improved fit. Both the 7-item S-LANSS and the
6-item S-LANSS showed no misfitting persons and no
evidence of response dependency, DIF, or multidimen-
sionality. Item 6 (“gently” rubbing feels different in the
“painful area”) was significant, as determined by ANOVA
(F[2,116]  5.16, P  0.007) following removal of item 4
(Table 3). Because deletion of item 6 made both fit and the
PSI worse, the item was retained. S-LANSS was poorly
targeted (Figure 2); there were gaps in measurement,
meaning that the full range of the trait was not covered.
Pain correlations. Rasch-transformed painDETECT and
S-LANSS scores shared a stronger correlation with each
other than with measures of pain severity (Table 4). The
association between painDETECT and S-LANSS remained
strong after controlling for ICOAP scores for intermittent
and constant pain (partial  0.58 [95% CI 0.46, 0.67], P
0.0001). The correlations between the questionnaires were
very similar when the standard scoring systems were used
instead of the Rasch-converted scores.
PPTs. Of the 114 patients contacted by telephone, 77
were included in the PPT substudy. Those who were not
included either were not eligible or were unwilling to
participate. Of the 76 patients who responded, 34 (45%)
self-reported pain only in their knee(s) (29% unilateral
and 16% bilateral), and 42 (55%) also reported pain in
other areas. Demographic characteristics are shown in
Table 1. Patients in the PPT substudy did not differ signif-
icantly from those whose data were used for ROC curve
analysis and Rasch analysis with respect to demographics
or pain scores, except that patients in the PPT substudy
reported a significantly shorter duration of pain (P 0.05).
The sternum and anterior tibia had significantly lower
PPTs (more sensitive) compared with the medial joint line
(P  0.01). Higher painDETECT scores were associated
with lower PPTs at each site, both in univariate analyses
(sternum,   0.35 [95% CI 0.54, 0.13]; medial tibio-
femoral joint line,   0.32 [95% CI 0.52, 0.08];
anterior tibia,   0.34 [95% CI 0.52, 0.11]; P  0.01
[n  6872]), and after controlling for ICOAP scores (ster-
Table 3. Final fit statistics for the individual items
Item Location SE
Fit
residual 2 P F P
painDETECT
1 & 2. “Burning sensation”/“tingling or prickling sensation” 0.03 0.04 0.00 0.41 0.81 0.17 0.84
3. “Light touching” painful 0.34 0.08 0.55 7.79 0.02 4.97 0.01
4. “Sudden pain attacks” 0.63 0.06 0.58 0.79 0.67 0.67 0.52
5. “Cold or heat” painful 0.77 0.08 0.74 1.67 0.43 0.79 0.46
6. “Numbness” sensation 0.10 0.07 0.63 0.71 0.70 0.42 0.66
7. “Slight pressure” pain 0.10 0.07 1.20 0.44 0.80 0.30 0.74
9. “Does your pain radiate” 0.46 0.17 2.37 0.69 0.71 0.26 0.78
S-LANSS*
1. “Pins and needle” sensations 0.19 0.21 1.41 0.30 0.86 0.05 0.95
2. “Painful area change color” 1.13 0.23 0.85 3.83 0.15 1.27 0.28
3. “Skin abnormally sensitive to touch” 0.24 0.20 0.65 7.07 0.03 4.95 0.01
5. “Burning pain” 0.10 0.20 0.64 0.93 0.63 0.59 0.55
6. “Gently” rubbing feels different in “painful area” 0.04 0.20 0.74 7.19 0.03 5.16 0.01
7. “Gently” pressing feels different in “painful area” 1.42 0.22 0.04 3.12 0.21 1.39 0.25
* S-LANSS  Self-Report Leeds Assessment of Neuropathic Symptoms and Signs.
Figure 2. Person-item threshold distributions for painDETECT
(A) and Self-Report Leeds Assessment of Neuropathic Symptoms
and Signs (S-LANSS) (B). The top part of each figure shows the
distribution of persons along the Rasch-estimated level of neuro-
pathic pain (x-axis). The lower part of each figure shows the
distribution of items. Given good targeting, the 2 distributions
should line up such that the range of neuropathic pain considered
by the items matches the range of neuropathic pain expressed by
the patients.
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num,   0.29 [95% CI 0.49, 0.06]; medial tibiofemo-
ral joint line,   0.37 [95% CI 0.56, 0.14]; anterior
tibia,   0.31 [95% CI 0.51, 0.08]; P  0.01 [n 
68–71]). Correlations between the PPT sites and the
ICOAP (constant subscale   0.20 to 0.08, P  0.05
[n  72–76]; intermittent subscale   0.08 to 0.07, P 
0.05 [n  73–76]) and NRS (  0.21 to 0.12, P  0.05
[n  73–77]) scores indicated that the associations were
stronger between PPTs and painDETECT than between
PPTs and measures of pain severity. Standard scores for
painDETECT and ICOAP produced similar correlations.
DISCUSSION
The characteristics of OA-related pain are diverse, and
the quality of this pain suggests mechanisms overlapping
with neuropathic pain. In this study, we showed that
painDETECT (with 1 item removed) may function as a
measure of neuropathic pain–like symptoms in OA, but
that S-LANSS does not function well as a measurement
scale. The pain characteristics measured by painDETECT
were associated with widespread reductions in PPTs.
The mechanisms of OA pain remain incompletely un-
derstood but may include changes in the joint and changes
in central pain processing (30). The current data confirm
previous findings that symptoms characteristic of neuro-
pathic pain are reported by some patients with OA (5).
PainDETECT and S-LANSS performed well as classifica-
tion questionnaires in previous studies (3,4) and catego-
rized neuropathic pain in 27% and 30% of this sample,
respectively. However, although each questionnaire clas-
sified neuropathic pain in similar proportions of patients,
agreement between the questionnaires was only fair, with
74% of patients classified similarly by both question-
naires. Adjusting the cutoffs of either questionnaire had
little impact on agreement. Tampin et al (31) reported
similar results using LANSS and painDETECT in individ-
uals with neck and upper limb pain (  0.21). Further
research is required to determine which tool provides the
most accurate classification of pain mechanisms in OA.
PainDETECT, with removal of 1 item, displayed good fit
to the Rasch model and was relatively well targeted to the
sample, supporting its measurement properties. Although
additional items that assess lower trait levels would be
useful to fully capture the trait range, precision at this end
of the scale is perhaps of reduced importance. Instead,
focus should be on individuals with higher trait levels
who may benefit from interventions addressing neuro-
pathic pain–like symptoms.
S-LANSS performed less well as a measurement scale.
Misfitting items were observed, and the PSI was low, rais-
ing concerns about the reliability of the fit statistics and
the ability of the scale to discern distinct strata within the
sample (32). Furthermore, the scale was poorly targeted
and would benefit from additional items. Similar results
were observed in another study examining fit between the
LANSS and the Rasch model (13), which suggests that
both versions of this questionnaire may be best suited as
screening tools.
Although some characteristics distinguish painDETECT
and S-LANSS, they shared a stronger association with
each other than with measures of pain severity. The cor-
relation between painDETECT and S-LANSS remained
strong when controlling for pain severity. Both question-
naires appear to address a coherent phenotype in patients
with knee OA, despite the aforementioned differences in
pain classifications. MPQ PRI scores exhibited similar as-
sociations with painDETECT, S-LANSS, and measures of
pain severity, possibly because the MPQ considers neuro-
pathic-like as well as nociceptive-like characteristics
(2,33).
PainDETECT scores are increased in patients with fibro-
myalgia, a condition characterized by widespread pain
and tenderness associated with abnormal central pain pro-
cessing but without demonstrable neuropathology (8,34).
Widespread reductions in PPTs are common in patients
with OA (10) or fibromyalgia (35) and reflect augmented
central pain processing. This study showed that low
PPTs across different body sites were associated with high
painDETECT scores in patients with knee OA, even after
adjusting for pain severity. PainDETECT scores have also
been associated with pain thresholds in general popula-
tion cohorts (9). High painDETECT scores may be a surro-
gate measure of augmented central pain processing (11)
rather than necessarily indicating neuropathology in pa-
tients with OA. There was a time delay between question-
naire completion and PPT testing, which may have caused
the strength of associations between painDETECT and
PPTs to be underestimated. Further work could explore
this by asking participants to complete the painDETECT
questionnaire at the time of PPT testing.
Another limitation of the study is that non-OA knee pain
may have confounded the results. Individuals with central
pain augmentation frequently report widespread pain, and
53% of the patients in this study reported pain at another
site(s) in addition to the knee. Patients with known fibro-
myalgia (based on self report or case note review) were
excluded, but the patients were not classified as having
or not having fibromyalgia. Pain mechanisms in fibromy-
algia may overlap with those in OA (36), and exclusion
of patients with features of fibromyalgia could have
biased the OA sample. Although the patients were asked
to respond with reference to their knee pain (5), pain at
other sites may have influenced responses to the generic
pain questionnaires (e.g., the MPQ), which were not al-
tered to be knee specific. It is not possible to infer causality
from the associations in this cross-sectional study, and
further work is required to determine whether knee OA
leads to neuropathology, whether alterations in central
pain processing lead to pain characteristics shared with
neuropathic pain, or whether a subgroup of patients are
predisposed to experience knee OA with neuropathic
symptomology. Further work is also required to determine
whether the findings in patients with OA-related knee
pain are generalizable to other patient populations.
Neuropathic pain is classified as pain caused by a lesion
or disease of the somatosensory nervous system (37). Neu-
ropathy may contribute directly to OA knee pain through
peripheral nerve damage within the joint (38), but there is
currently no gold standard by which to identify neuropa-
thy within articular nociceptive pathways. The screening
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questionnaires were originally validated by comparing pa-
tients in whom neuropathic pain was diagnosed by a phy-
sician and patients with arthritis and other nociceptive
conditions (3,4). Although symptoms may suggest neurop-
athy, it remains uncertain which questionnaire or which
cutoff is most accurate in identifying neuropathic pain
mechanisms in OA. In contrast, associations with PPTs at
sites distant from the affected joints provide evidence that
painDETECT scores reflect central pain processing in pa-
tients with knee OA. Central processing may augment pain
severity and contribute to overlapping pain qualities asso-
ciated with either nerve damage or joint damage.
In conclusion, 30% of the study sample had scores
above the cutoff on painDETECT or S-LANSS, potentially
representing a phenotype within knee OA. This phenotype
shares characteristics with neuropathic pain and is asso-
ciated with augmented central pain processing, as indi-
cated by widespread reductions in PPTs. The data suggest
that painDETECT and S-LANSS target a discrete pheno-
type in knee OA, reflecting pain quality as distinct from
pain severity. In addition, Rasch analysis showed that
painDETECT may be used as a measurement scale for
these phenotypic characteristics. However, agreement be-
tween painDETECT and S-LANSS for pain classification
was only fair, and it is currently uncertain which tool is
more accurate. Further work with a larger sample size is
required to develop these questionnaires as stratification
and outcome tools for testing treatments directed at central
processing in patients with knee OA.
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